Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ETNB Stock Forecast 2026-2027
$14.84
Current Price
$2.20B
Market Cap
Buy 2
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to ETNB Price Targets
+270.6%
To High Target of $55.00
+75.2%
To Median Target of $26.00
-2.3%
To Low Target of $14.50
ETNB Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+144.9%
1 Year Change
0.0%
Year-to-Date Change
-1.5%
From 52W High of $15.06
+256.7%
From 52W Low of $4.16
📊 TOP ANALYST CALLS
Did ETNB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if 89bio is one of their latest high-conviction picks.
Latest ETNB Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, ETNB has a neutral consensus with a median price target of $26.00 (ranging from $14.50 to $55.00). The overall analyst rating is Buy (7.3/10). Currently trading at $14.84, the median forecast implies a 75.2% upside. This outlook is supported by 2 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Andrew S. Fein at HC Wainwright & Co., suggesting a 2.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ETNB Analyst Ratings
2
Buy
4
Hold
0
Sell
ETNB Price Target Range
Low
$14.50
Average
$26.00
High
$55.00
Current: $14.84
Latest ETNB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ETNB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 19, 2025 | HC Wainwright & Co. | Andrew S. Fein | Neutral | Downgrade | $14.50 |
| Sep 19, 2025 | Wolfe Research | Andy Chen | Peer Perform | Downgrade | $N/A |
| Sep 19, 2025 | Raymond James | Steven Seedhouse | Market Perform | Downgrade | $N/A |
| Sep 4, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Assumes | $32.00 |
| Aug 25, 2025 | B of A Securities | Alexandria Hammond | Buy | Maintains | $29.00 |
| Aug 8, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $11.00 |
| Mar 14, 2025 | Goldman Sachs | Andrea Newkirk | Neutral | Initiates | $11.00 |
| Mar 13, 2025 | Citigroup | Geoff Meacham | Buy | Initiates | $25.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $21.00 |
| Feb 4, 2025 | Wolfe Research | Andy Chen | Outperform | Initiates | $N/A |
| Jan 31, 2025 | UBS | Eliana Merle | Buy | Maintains | $38.00 |
| Jan 21, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $29.00 |
| Jan 2, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $29.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $29.00 |
| Nov 8, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Maintains | $49.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $29.00 |
| Aug 6, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Maintains | $53.00 |
| Aug 6, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $12.00 |
| Aug 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $29.00 |
| Jul 1, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $29.00 |
89bio Inc. (ETNB) Competitors
The following stocks are similar to 89bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
89bio Inc. (ETNB) Financial Data
89bio Inc. has a market capitalization of $2.20B with a P/E ratio of -4.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -86.9%.
Valuation Metrics
Market Cap
$2.20B
Enterprise Value
$1.68B
P/E Ratio
-4.2x
PEG Ratio
-0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+25.5%
Current Ratio
15.2x
Debt/Equity
7.2x
ROE
-86.9%
ROA
-49.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
89bio Inc. (ETNB) Business Model
About 89bio Inc.
What They Do
Develops therapies for liver and metabolic diseases.
Business Model
89bio Inc. focuses on creating innovative biopharmaceutical treatments, primarily for nonalcoholic steatohepatitis (NASH) and metabolic disorders. The company generates revenue by advancing its therapies through clinical trials, aiming for eventual commercialization and market access to address critical healthcare needs.
Additional Information
Operating in the biotech and pharmaceutical industry, 89bio Inc. is positioned to transform patient outcomes by targeting underserved medical conditions. Its work is significant for various stakeholders, including healthcare providers and investors, as it aims to introduce novel therapeutic solutions that could change treatment approaches for complex diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
93
CEO
Mr. Rohan Palekar
Country
United States
IPO Year
2019
Website
www.89bio.com89bio Inc. (ETNB) Latest News & Analysis
Latest News
3 Investable Laggards In An Overbought Market
5 months ago
Quick Summary
The market is in overbought territory, largely driven by tech gains from the AI Revolution. Despite a government shutdown and ongoing U.S.-China trade tensions, equities reach all-time highs.
Why It Matters
Overbought conditions signal potential market corrections, while reliance on tech gains raises concerns. Ongoing government shutdown and U.S.-China tensions add further risk to equities.
Source: Seeking Alpha
Market Sentiment:
Neutral
My Top 3 Pharma Stocks
5 months ago
Quick Summary
Pharma stocks are underappreciated despite beating consensus estimates and offering high dividend yields compared to IT and oil sectors, amid rising global health issues.
Why It Matters
Rising health issues boost demand for pharmaceuticals, while underappreciated stocks with strong earnings and dividends present attractive investment opportunities.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
89bio, Inc. is proposed to be sold to Roche for $14.50 per share in cash, plus potential contingent payments of up to $6.00, under investigation by Kahn Swick & Foti, LLC.
Why It Matters
The investigation into 89bio's sale to Roche could impact share price and investor sentiment, as legal scrutiny may affect the deal's completion and final payouts.
Source: Business Wire
Market Sentiment:
Neutral
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB)
6 months ago
Quick Summary
Juan Monteverde of Monteverde & Associates PC has successfully recovered millions for shareholders and is listed as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
Why It Matters
Recognition of Monteverde & Associates as a top firm in class action recoveries signals strong legal support for shareholders, potentially boosting investor confidence in ongoing and future cases.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
89bio, Inc. is being investigated regarding its proposed sale to Roche Holding AG for $14.50 per share, plus potential contingent payments of up to $6.00 per share.
Why It Matters
The investigation into 89bio's sale to Roche may signal potential legal issues or complications affecting the deal, which could impact share pricing and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
3 Potential Biotech Acquisition Targets
6 months ago
Quick Summary
Recent speculation on Seeking Alpha highlights several biotech/biopharma firms as potential buyout targets, noting their strong balance sheets and promising futures.
Why It Matters
Speculation of potential buyouts in biotech suggests increased acquisition activity, which could drive stock prices up for targeted firms and attract investor interest in the sector.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About ETNB Stock
What is 89bio Inc.'s (ETNB) stock forecast for 2026?
Based on our analysis of 18 Wall Street analysts, 89bio Inc. (ETNB) has a median price target of $26.00. The highest price target is $55.00 and the lowest is $14.50.
Is ETNB stock a good investment in 2026?
According to current analyst ratings, ETNB has 2 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ETNB stock?
Wall Street analysts predict ETNB stock could reach $26.00 in the next 12 months. This represents a 75.2% increase from the current price of $14.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is 89bio Inc.'s business model?
89bio Inc. focuses on creating innovative biopharmaceutical treatments, primarily for nonalcoholic steatohepatitis (NASH) and metabolic disorders. The company generates revenue by advancing its therapies through clinical trials, aiming for eventual commercialization and market access to address critical healthcare needs.
What is the highest forecasted price for ETNB 89bio Inc.?
The highest price target for ETNB is $55.00 from at , which represents a 270.6% increase from the current price of $14.84.
What is the lowest forecasted price for ETNB 89bio Inc.?
The lowest price target for ETNB is $14.50 from Andrew S. Fein at HC Wainwright & Co., which represents a -2.3% decrease from the current price of $14.84.
What is the overall ETNB consensus from analysts for 89bio Inc.?
The overall analyst consensus for ETNB is neutral. Out of 18 Wall Street analysts, 2 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $26.00.
How accurate are ETNB stock price projections?
Stock price projections, including those for 89bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 16, 2026 5:21 AM UTC